Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001698-25
    Sponsor's Protocol Code Number:LIVERHOPE_EFFICACY
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-07-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-001698-25
    A.3Full title of the trial
    Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical trial.
    Eficacia de la combinación de simvastatina y rifaximina en pacientes con cirrosis descompensada para prevenir el desarrollo de ACLF: ensayo clínico multicéntrico aleatorizado, doble-ciego, controlado con placebo.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis
    Eficacia de la combinación de simvastatina y rifaximina en pacientes con cirrosis descompensada
    A.4.1Sponsor's protocol code numberLIVERHOPE_EFFICACY
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIDIBAPS
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportH2020
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationHospital Clínic
    B.5.2Functional name of contact pointPere Ginés
    B.5.3 Address:
    B.5.3.1Street AddressVillarroel, 170
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08036
    B.5.3.4CountrySpain
    B.5.4Telephone number+349322754001713
    B.5.5Fax number+34932279877
    B.5.6E-mailpgines@clinic.cat
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRifaximin-EIR
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRIFAXIMIN
    D.3.9.1CAS number 80621-81-4
    D.3.9.4EV Substance CodeSUB10312MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Sivastin
    D.2.1.1.2Name of the Marketing Authorisation holderAlfasigma SpA
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSivastin
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSIMVASTATIN
    D.3.9.2Current sponsor codeSIVASTIN
    D.3.9.4EV Substance CodeSUB10529MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with decompensated cirrhosis
    Pacientes con cirrosis descompensada
    E.1.1.1Medical condition in easily understood language
    Patients with decompensated cirrhosis
    Pacientes con cirrosis descompensada
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10009209
    E.1.2Term Cirrhosis bilary
    E.1.2System Organ Class 100000004871
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of oral administration of Simvastatin plus Rifaximin in halting the progression of decompensated cirrhosis as assessed by the time to first incidence of ACLF during treatment period.
    Evaluar la eficacia de la administración oral de simvastatina y rifaximina para prevenir el desarrollo de la cirrosis descompensada mediante la evaluación del tiempo hasta la primera incidencia de ACLF durante el período de tratamiento.
    E.2.2Secondary objectives of the trial
    -Time to transplant-free survival and incidence
    -Severity of ACLF
    -Frequency of hospital admissions due to complications of cirrhosis
    -Development/worsening of complications of cirrhosis
    -Systemic inflammatory response
    -Plasma and urine levels of biomarkers
    -Vasoactive hormones
    -Blood levels of bacterial DNA
    -Changes in fecal microbiome composition
    -Liver function, evaluated by MELD CLIF-C AD and Child-Pugh Scores
    -Quality of life, functional assessment and minimal hepatic encephalopathy, as assessed by CLDQ , Liver Frailty score and PHES questionnaires
    -Stigmatization in patients as assessed by a specific questionnaire
    -Appearance of muscle toxicity assessed by specific statin-associated myopathy questionnaire
    -Genetic polymorphisms of statins membrane transporter OATP1B1
    -Muscle or liver toxicity assessed by analytical changes
    -Type and severity of treatment-related adverse events
    -Annualized incidence of ACLF
    -Time to overall and time to disease related survival
    -Tiempo de supervivencia libre de trasplante e incidencia
    -Gravedad de ACLF
    -Frecuencia de ingresos hospitalarios debidos a complicaciones
    -Desarrollo/empeoramiento de las complicaciones de la cirrosis
    -Respuesta inflamatoria mediante niveles plasmáticos y en orina de biomarcadores
    -Hormonas vasoactivas
    - Niveles de DNA bacteriano
    -Cambios en la composición del microbioma fecal
    -Función hepática mediante MELD, CLIF-C AD y Child-Pugh scores
    -Calidad de vida, evaluación funcional y encefalopatía hepática mínima mediante los cuestionarios CLDQ, Liver Frailty y PHES
    -Estigmatización en pacientes con cirrosis descompensada
    -Aparición de toxicidad muscular a través del cuestionario específico de miopatía
    -Polimorfismo genético de OATP1B1
    -Toxicidad muscular o hepática
    -Tipo y gravedad de los acontecimientos adversos relacionados con el tratamiento
    -Incidencia anualizada de ACLF
    -Tiempo de supervivencia global y tiempo de supervivencia relacionada con la enfermedad
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Patients included into the study must meet all the following criteria:
    1. Age ≥ 18 years old.
    2. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any aetiology may be included. However, patients with cirrhosis due to autoimmune hepatitis must be on stable corticosteroid dose for ≥3-month period before study inclusion.
    3. Child-Pugh B patients or Child-Pugh C patients (up to 12 points).
    4. Women of child-bearing potential* must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods during the study. Highly effective contraceptive methods will include: intrauterine device, bilateral tubal occlusion, vasectomized partner and sexual abstinence. Hormonal contraceptive methods will be avoided due to the risk of adverse events and impairment of liver function.
    Los pacientes incluidos en el estudio deberán cumplir los siguientes criterios:
    1. Edad ≥ 18 años.
    2. Cirrosis definida según criterios clínicos estándar y resultados de ultrasonográficos y/o histología. Pueden incluirse pacientes con cirrosis de cualquier etiología. Los pacientes con cirrosis de etiología autoinmune en tratamiento con corticosteroides deberán estar con dosis estable de corticosteroides por ≥ 3 meses, previa inclusión en el estudio.
    3. Pacientes con Child-Pugh B y C (hasta 12 puntos).
    4. Las mujeres en edad fértil* deben tener una prueba negativa de embarazo en suero antes de la inclusión en el estudio y deben comprometerse a utilizar métodos anticonceptivos altamente eficaces (dispositivo intrauterino, oclusión tubárica bilateral, pareja vasectomizada y abstinencia sexual).
    Se evitarán métodos anticonceptivos hormonales para evitar el riesgo de acontecimientos adversos y deterioro de la función hepática.
    E.4Principal exclusion criteria
    Potential participants who meet any of the following criteria will be excluded from participation in this study:
    1. Patients on treatment with statins or rifaximin up to one month before study inclusion.
    2. Patients with contraindications for statins or rifaximin therapy.
    3. Known hypersensitivity to simvastatin or rifaximin (or rifamycin derivatives).
    4. Patients with CK elevation of 50% or more above the upper limit of normal at study inclusion.
    5. Patients on treatment with potent inhibitors of CYP3A4 enzyme (see section 5.2: Concomitant, nonpermitted and permitted medication).
    6. Patients on treatment with drugs with potential interactions with simvastatin (see section 5.2: Concomitant, nonpermitted and permitted medication).
    7. Patients with previous history of myopathy.
    8. Patients with previous history of intestinal obstruction or those who are at increased risk of this complication.
    9. Patients with ACLF according to the criteria published by Moreau et al. (see appendix 2).
    10. Serum creatinine ≥2 mg/dL (176.8 μmol/L).
    11. Serum bilirubin>5 mg/dL (85.5 μmol/L).
    12. INR ≥2.5.
    13. Bacterial infection within 10 days before study inclusion.
    14. Gastrointestinal bleeding within 10 days before study inclusion.
    15. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the New-Haven classification.
    16. Patients with active hepatocellular carcinoma or history of hepatocellular carcinoma that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.
    17. Patients on antiviral therapy for HCV or those who have received it within the last 6 months.
    18. Severe alcoholic hepatitis requiring corticosteroid therapy (Maddrey’s Discriminant function ≥ 32 and/or ABIC score > 6.7).
    19. Patients with active alcohol consumption of more than 21 units per week.
    20. HIV infection.
    21. Patients with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD >2, chronic kidney disease with serum creatinine >2mg/dL or under renal replacement therapy.
    22. Patients with current extra hepatic malignancies including solid tumours and hematologic disorders.
    23. Pregnancy or breastfeeding.
    24. Patients included in other clinical trials in the month before inclusion.
    25. Patients with mental incapacity, language barrier, bad social support or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.
    26. Refusal to give informed consent.
    Los potenciales participantes que cumplan algunos de los siguientes criterios serán excluidos del estudio:
    1. Pacientes en tratamiento con estatinas o rifaximina durante el mes antes de la inclusión en el estudio.
    2. Pacientes con contraindicaciones para la rifaximina o la simvastatina.
    3. Hipersensibilidad conocida a la rifaximina (o derivados de la rifamicina) o a la simvastatina.
    4. Pacientes con aumento de los niveles de CK del 50% o superiores del límite alto de la normalidad en el momento de la inclusión en el estudio.
    5. Pacientes que reciban tratamiento con inhibidores potentes de la enzima CYP3A4 (ver sección 5.2: Medicación concomitante no permitida y permitida).
    6. Pacientes que reciban tratamiento con fármacos con interacciones potenciales con la simvastatina (ver sección 5.2: Medicación concomitante no permitida y permitida).
    7. Pacientes con antecedentes de miopatía.
    8. Pacientes con antecedente o con riesgo aumentado de obstrucción intestinal.
    9. Pacientes con ACLF de acuerdo con los criterios de Moreau et al. (ver Anexo 2).
    10. Creatinina sérica ≥ 2 mg/dL (176,8 μmol/L).
    11. Bilirrubina sérica > 5 mg/dL (85,5 μmol/L).
    12. INR ≥ 2,5.
    13. Infección bacteriana en los 10 días previos a la inclusión.
    14. Hemorragia gastrointestinal en los 10 días previos a la inclusión.
    15. Encefalopatía hepática clínica en el momento de la inclusión, definida como grado II-IV según la clasificación New-Haven.
    16. Pacientes con carcinoma hepatocelular activo o antecedentes de carcinoma hepatocelular en remisión durante menos de seis meses por HCC uninodular o por menos de 12 meses por HCC multinodular según los criterios de Milán.
    17. Pacientes en tratamiento antiviral para el VHC o tratados en los últimos 6 meses.
    18. Hepatitis alcohólica severa que requiera tratamiento con corticoides (Índice de Maddrey ≥ 32 y/o score ABIC > 6,7).
    19. Pacientes con consumo activo de alcohol de más de 21 unidades de bebida a la semana.
    20. Infección por VIH.
    21. Pacientes con historia de enfermedad extrahepática significativa con mal pronóstico a corto plazo, incluyendo insuficiencia cardiaca congestiva grado III/IV de la clasificación de New York Heart Association, enfermedad pulmonar obstructiva crónica GOLD >2, enfermedad renal crónica con creatinina sérica > 2 mg/dL o en tratamiento con hemodiálisis.
    22. Pacientes con cáncer actual extrahepático, incluyendo tumores sólidos o enfermedades hematológicas.
    23. Embarazo o lactancia.
    24. Pacientes incluidos en otros ensayos clínicos en el último mes.
    25. Pacientes con incapacidad mental, barrera lingüística mayor, pobre soporte social o alguna otra razón que el investigador considere que no permita una adecuada comprensión, cooperación o seguimiento del estudio.
    26. No otorga consentimiento informado.
    E.5 End points
    E.5.1Primary end point(s)
    Time to ACLF in the two groups during follow-up..
    Tiempo hasta ACLF en los dos grupos de tratamiento durante el período de seguimiento.
    E.5.1.1Timepoint(s) of evaluation of this end point
    months 1, 3, 6, 9 and 12
    meses 1, 3, 6, 9 y 12
    E.5.2Secondary end point(s)
    -Time to transplant-free survival. Incidences at 1 month, 3 months, 6 months, 9 months and 12 months
    -Severity of ACLF assessed by number and types of organ failures at baseline, 1 month, 3 months, 6 months, 9 months and 12 months
    -Frequency of hospital admissions due to complications of cirrhosis assessed at baseline, 1 month, 3 months, 6 months, 9 months and 12 months
    -Development/worsening of individual complications of cirrhosis (ascites, acute kidney injury, gastrointestinal bleeding, hepatic encephalopathy (HE), bacterial infections) assessed at baseline and at 1, 3, 6, 9 and 12 months
    -Changes from baseline in systemic inflammatory response, evaluated by measurement in a large array of plasma cytokine levels including, but not limited to TNFα, IL-6, IL8, IL-10, IL-1β, IFN-ɣ, G-CSF, VCAM, VEGF, as well as an oxidized form of albumin, human nonmercaptalbumin-2 (HNA2), dimethylarginine (ADMA and SDMA) at 3, 6 and 12 months
    -Changes from baseline in plasma biomarkers (FABP4, sCD-163), von Willebrand factor (vWF) and urine biomarkers (NGAL, MCP-1, and albumin) at 3 , 6 and 12 months
    -Changes from baseline in vasoactive hormones: plasma renin concentration, plasma norepinephrine and plasma copeptin at 3, 6 and 12 months
    -Changes from baseline in blood levels of bacterial DNA or bacterial products at 3, 6 and 12 months
    -To evaluate changes in microbiome composition by analysis of microbial genes and signature in patients included in the study at baseline and 3, 6 and 12 months
    -Changes from baseline in liver function, evaluated by MELD score, CLIF-AD score and Child Pugh Score at 1 3, 6, 9 and 12 months.
    -Quality of life, functional assessment and in Minimal Hepatic Encephalopathy during treatment period, as assessed by CLDQ, Liver Frailty Index and PHES questionnaires at baseline and 1 3, 6, 9 and 12 months
    -Changes from baseline in stigmatization in patients with decompensated cirrhosis as assessed by a previously validated specific questionnaire at 3 months, 6 months and 12 months.
    -Appearance of muscle toxicity at baseline, 1 month, 3 months, 6 months, 9 months and 12 months as defined using a specific statin-associated myopathy questionnaire
    -Assessment of genetic polymorphisms of statins membrane transporter OATP1B1 in all the patients included in the study.
    -To evaluate liver or muscle toxicity as defined by analytical changes from baseline in liver or muscle enzymes (transaminases, alkaline phosphatase and creatine kinase) at 1 month, 3 months, 6 months, 9 months and 12 months.
    -Proportion of patients and severity of treatment-related adverse events during the study period.
    -Annualized incidence of ACLF.
    -Time to overall and time to disease related survival.
    1. Tiempo de supervivencia libre de trasplante. Incidencias al mes 1, mes 3, mes 6, mes 9 y mes 12.
    2. Gravedad de ACLF mediante la evaluación de número y tipo de fallos orgánicos en la visita basal y al mes 1, mes 3, mes 6, mes 9 y mes 12.
    3. Frecuencia de ingresos hospitalarios debidos a complicaciones de la cirrosis durante la visita basal y al mes 1, mes 3, mes 6, mes 9 y mes 12.
    4. Desarrollo/empeoramiento de las complicaciones de la cirrosis (ascitis, insuficiencia renal, sangrado gastrointestinal, encefalopatía hepática (EH), infecciones bacterianas) en la visita basal, al mes 1, mes 3, mes 6, mes 9 y mes 12
    5. Cambios desde los valores basales en los niveles plasmáticos de citoquinas, evaluado mediante la medición en una gran variedad de niveles de citoquinas en plasma que incluyen, pero se limitan a TNFα, IL-6, IL8, IL-10, IL-1β, IFN-ɣ, G-CSF, VCAM, VEGF, así como la forma oxidada de albúmina, nonmercaptoalbúmina humana 2 (HNA2), dimetilarginina (ADMA y SDMA) a los 3, 6 y 12 meses.
    6. Cambios desde los niveles basales en los biomarcadores plasmáticos (FABP4 y CD-163), factor von Willebrand y los biomarcadores en orina (NGAL, MCP-1, y albúmina) a los 3, 6 y 12 meses.
    7. Cambios desde los niveles basales en hormonas vasoactivas: renina plasmática, norepinefrina plasmática y copeptina plasmática a los 3, 6 y 12 meses.
    8. Cambios desde los valores basales en los niveles en sangre de ADN bacteriano o productos bacterianos a los 3, 6 y 12 meses.
    9. Evaluación de los cambios en la composición del microbioma mediante el análisis de genes microbianos y perfiles en pacientes incluidos en el estudio a la visita basal y a los 3, 6 y 12 meses.
    10. Cambios respecto a la visita basal en la función hepática evaluada mediante MELD score, CLIF-AD score y Child Pugh Score (ver Anexo 4) al mes 1 y a los 3, 6, 9 y 12 meses.
    11. Calidad de vida, evaluación funcional y encefalopatía hepática mínima durante el período de tratamiento, mediante la evaluación de los cuestionarios CLDQ (Cuestionario para pacientes con enfermedad hepática crónica), Liver Frailty score y PHES (Test de encefalopatía hepática mínima) en la visita basal, al mes 1 y a los 3, 6, 9 y 12 meses (ver anexos 5, 6 y 7).
    12. Cambios respecto a la visita basal en la estigmatización en los pacientes con cirrosis descompensada, evaluada mediante un cuestionario específico (ver Anexo 8) a los 3, 6 y 12 meses.
    13. Aparición de toxicidad muscular en la visita basal, mes 1 y a los 3, 6, 9 y 12 meses mediante el cuestionario específico de miopatía relacionado con el uso de estatinas (ver Anexo 3).
    14. Evaluación del polimorfismo genético del transportador de membrana de estatinas, OATP1B1, en todos los pacientes incluidos en el estudio.
    15. Toxicidad muscular o hepática evaluada mediante cambios analíticos respecto la visita basal en enzimas hepáticos o musculares (transaminasas, fosfatasa alcalina y creatin kinasa) al mes 1 y a los 3, 6, 9 y 12 meses.
    16. Proporción de pacientes y gravedad de acontecimientos adversos relacionados con el tratamiento durante el período de tratamiento.
    17. Incidencia anualizada de ACLF.
    18. Tiempo de supervivencia global y tiempo de supervivencia relacionada con la enfermedad.
    E.5.2.1Timepoint(s) of evaluation of this end point
    months 1, 3, 6, 9 and 12
    meses 1, 3, 6, 9 y 12
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA9
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months32
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months32
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 240
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 240
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state240
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 240
    F.4.2.2In the whole clinical trial 240
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Expected normal treatment
    Tratamiento clínico habitual
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-07-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-07-19
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-12-01
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 24 16:21:02 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA